Abivax Sa ADR (ABVX)

Apr 22, 2025, 4:05 PM EDT - 1 day ago

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Apr 22, 2025, 4:00 PM EDT - 1 day ago

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Mar 26, 2025, 5:05 PM EDT - 4 weeks ago

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Mar 24, 2025, 3:30 AM EDT - 4 weeks ago

Abivax Announces Full Year 2024 Financial Results

Feb 21, 2025, 2:30 AM EST - 2 months ago

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Jan 28, 2025, 2:30 AM EST - 3 months ago

Abivax Publishes 2025 Financial Calendar

Jan 23, 2025, 4:05 PM EST - 3 months ago

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

Jan 9, 2025, 11:35 AM EST - 3 months ago

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Dec 23, 2024, 4:05 PM EST - 4 months ago

Abivax Announces a Change to the Composition of its Board of Directors

Nov 19, 2024, 4:30 PM EST - 5 months ago

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Nov 14, 2024, 4:01 PM EST - 5 months ago

Abivax presents third quarter 2024 key financial information

Nov 13, 2024, 4:01 PM EST - 5 months ago

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Oct 7, 2024, 4:01 PM EDT - 7 months ago

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

Oct 3, 2024, 4:01 PM EDT - 7 months ago

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Oct 3, 2024, 2:31 AM EDT - 7 months ago

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

Sep 26, 2024, 2:30 AM EDT - 7 months ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Sep 25, 2024, 4:01 PM EDT - 7 months ago

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

Sep 9, 2024, 4:01 PM EDT - 8 months ago

Abivax presents first-half 2024 financial results

Aug 6, 2024, 2:30 AM EDT - 9 months ago

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

Jul 15, 2024, 4:00 PM EDT - 10 months ago

Abivax Provides Operational and Key Program Update

Jun 4, 2024, 4:10 PM EDT - 11 months ago

Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

Apr 8, 2024, 1:25 PM EDT - 1 year ago

ABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call Transcript

Apr 2, 2024, 2:30 AM EDT - 1 year ago

Abivax reports 2023 financial results and operational update

Feb 13, 2024, 2:50 AM EST - 1 year ago

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)

Oct 26, 2023, 4:00 AM EDT - 1 year ago

Citi Appointed as Depositary Bank for Abivax SA's ADR Program

Oct 24, 2023, 4:15 PM EDT - 1 year ago

Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market

Oct 21, 2023, 1:25 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Big Launches And New Filings Keep The IPO Market Moving

HG JL MNR MVRK NCL WAY

Oct 20, 2023, 10:00 AM EDT - 1 year ago

Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris

Oct 20, 2023, 9:15 AM EDT - 1 year ago

Abivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global Market

Oct 20, 2023, 3:00 AM EDT - 1 year ago

Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris

Oct 19, 2023, 6:48 AM EDT - 1 year ago

Abivax increases size of Nasdaq uplisting deal

Oct 18, 2023, 6:17 PM EDT - 1 year ago

Abivax Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Price Range

Oct 18, 2023, 5:20 PM EDT - 1 year ago

Abivax Readies $250 Million U.S. IPO For Drug Pipeline

Oct 16, 2023, 12:00 PM EDT - 1 year ago

Abivax Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq Listing

Oct 14, 2023, 4:40 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Birkenstock Missteps In Public Debut

BIRK ATPC GMM LRHC MNR PMEC PMNT

Oct 3, 2023, 1:05 PM EDT - 1 year ago

Abivax SA Starts U.S. IPO Process